# Regional blood flow signatures of opioidergic modulation of ketamine in
# major depressive disorder: a randomised crossover study

Luke A. Jelen[1,2], Owen O'Daly[1], Fernando O. Zelaya[1], James M. Stone[3,4],

Allan H. Young[1,2,5], Mitul A. Mehta[1]

1. Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny
Park, London, SE5 8AF, UK.
2. South London and Maudsley NHS Foundation Trust, London, UK
3. Brighton and Sussex Medical School (BSMS), University of Sussex, Brighton, UK.
4. Sussex Partnership NHS Foundation Trust, West Sussex, UK
5. Imperial College London, London, UK

11
12 Corresponding author: luke.jelen@kcl.ac.uk
13
14
**ORCiDs**
Jelen, LA: orcid.org/0000-0001-6398-5239
O'Daly O: orcid.org/0000-0001-5690-1252
Zelaya F: orcid.org/0000-0002-9525-1560
Stone, JM: orchid.org/0000-0003-3051-0135
Young, AH: orcid.org/0000-0003-2291-6952
Mehta, M: orcid.org/0000-0003-1152-5323

## Abstract:

**Importance:** Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. Ketamine acutely increases regional and global cerebral blood flow (CBF), yet opioid system influence on these changes remains unclear.

**Objective:** To investigate how opioid system modulation via naltrexone affects ketamine-induced CBF changes in individuals with major depressive disorder (MDD) and to explore the relationship between CBF changes and receptor density profiles.

**Design:** Randomised, double-blind, crossover study.

**Setting:** Single-site clinical research setting.

**Participants:** Twenty-six adults (18-50 years) diagnosed with MDD, all exhibiting inadequate response to at least two prior antidepressant treatments (medication and/or psychotherapy).

**Interventions:** Participants received either oral naltrexone (50 mg) or placebo, followed by intravenous ketamine (0.5 mg/kg over 40 minutes) during 3D pseudo-Continuous Arterial Spin Labelling (3D-pCASL) MRI.

**Main Outcome(s) and Measure(s):** Main outcomes were CBF changes, assessed using 3D-pCASL MRI, and their relationship with subjective effects (Clinician-Administered Dissociative States Scale [CADSS] and Psychotomimetic States Inventory [PSI]) and clinical outcomes (Montgomery-Åsberg Depression Rating Scale [MADRS] and Quick Inventory of Depressive Symptomatology Self-Report [QIDS-SR]). Exploratory outcomes included correlations between CBF changes and receptor density profiles (MOR, KOR, NMDA, mGluR5, GABAA, and GABAAα5).

**Results:** Ketamine significantly increased CBF in the subgenual, pregenual, and dorsal anterior cingulate cortices ($p < 0.05$, FWE-corrected), effects not attenuated by naltrexone. Under placebo pretreatment, CBF changes after ketamine in the pregenual anterior cingulate were associated with immediate subjective effects (PSI-delusional: $r = 0.56$, $p = 0.004$; PSI-perceptual distortion: $r = 0.64$, $p < 0.001$), and baseline CBF in the subgenual anterior cingulate cortex predicted day-one antidepressant response (MADRS: $r = 0.6$, $p = 0.002$; QIDS-SR: $r = 0.67$, $p < 0.001$). Naltrexone pretreatment disrupted these predictive relationships. Ketamine-induced CBF changes correlated with MOR, and mGluR5 receptor profiles, while naltrexone's interaction was linked to MOR and GABAAα5 (corrected for spatial autocorrelation, $p_{SA-corr} < 0.05$).

**Conclusions and Relevance:** This study demonstrates ketamine's effects on CBF in MDD are influenced by complex interactions between glutamatergic, opioidergic, and GABAergic systems. These findings provide mechanistic insights with potential implications for optimising ketamine-based treatments.

**Registration:** ClinicalTrials.gov Identifier: NCT04977674

# Introduction

At subanaesthetic doses, ketamine can produce rapid reductions in depressive symptoms and suicidal ideation, including in individuals with treatment-resistant depression (TRD) (1,2). Neuroimaging studies have explored ketamine's effects on brain structure, function, connectivity, neurochemistry, and metabolism, aiming to elucidate its therapeutic mechanisms (3). Most of the functional studies have employed blood oxygen-level-dependent (BOLD) MRI, using both resting-state and task-based paradigms (4–7). These studies consistently report alterations in brain activity and network functioning, but the relationship between these changes and symptom improvement, as well as the contributions of underlying neurotransmitter systems, remains unclear.

In addition to its primary action as an uncompetitive NMDA receptor antagonist, ketamine also modulates the opioid system (8,9). Preclinical and clinical evidence suggests that opioid system activation contributes to ketamine's rapid antidepressant effects (9–18). However, this relationship is not consistently observed across all studies (19–21). Understanding how opioid mechanisms influence ketamine's effects on brain activity and their relationship to clinical outcomes is crucial for clarifying its mechanism of action.

One fundamental aspect of ketamine's neurovascular effects is its impact on regional cerebral blood flow (rCBF), which may be mediated by both neurovascular coupling and direct vascular effects (22,23). While BOLD imaging indirectly reflects changes in brain activity through changes in CBF and in cerebral metabolic rate of oxygen consumption ($CMRO_2$) (24), arterial spin labelling (ASL) provides direct, quantitative measures of rCBF without ionising radiation or contrast agents (25). ASL has been used to examine the acute effects of psychoactive compounds, including ketamine (26), as well as opioid agonists and antagonists (27).

ASL and PET studies consistently show ketamine-induced rCBF increases in prefrontal, orbitofrontal, anterior cingulate, insular, and subcortical regions including the thalamus, caudate, putamen, and hippocampus (26,28–33). However, the relationship between these rCBF changes and antidepressant response is less consistent. Prior ASL studies in TRD patients have reported variable rCBF alterations following ketamine, with some studies associating these changes with clinical improvement (34–36).

While the effects of ketamine on rCBF have been characterised during intravenous (IV) administration in healthy individuals (26,28), no published studies have examined these effects in MDD patients during acute IV administration. Furthermore, the impact of opioid antagonism on ketamine-induced rCBF changes has not been tested in any population.

In this randomised, double-blind, crossover study, participants with MDD received two separate IV ketamine infusions during neuroimaging, each preceded by either the opioid antagonist naltrexone or placebo. Our primary neuroimaging outcome, previously reported (9), demonstrated that naltrexone attenuated the acute ketamine-induced increase in glutamate+glutamine (Glx) to total N-acetylaspartate (tNAA) ratio and the reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores on day 1 post-infusion. Here, we focus on the ASL outcomes, examining how naltrexone modulated ketamine's effects on rCBF. We hypothesised that ketamine would increase rCBF in regions implicated in emotional processing, including the subgenual, pregenual, and dorsal anterior cingulate cortex (sgACC, pgACC, dACC), as well as the thalamus, and that naltrexone would attenuate this effect (Clinicaltrials.gov: NCT04977674). Additionally, we explored the spatial relationship between ketamine-induced rCBF changes and receptor density profiles to better understand the involvement of underlying neurotransmitter systems.

## Methods

### Study Design and Procedures

Ethical approval was obtained from the London – City & East Research Ethics Committee (Reference: 21/LO/0334) and all participants provided written informed consent (ClinicalTrials.gov registration: NCT04977674).

Participants completed two study visits, each involving a double-blind oral pretreatment (naltrexone 50 mg or placebo, ascorbic acid 50 mg), administered 1 hour before a 40-minute IV ketamine infusion (0.5 mg/kg) during MRI. The two visits were separated by a 2–4-week washout period (**Figure 1A**). Pretreatment order randomisation was computer-generated using block randomisation (block size: 4) stratified by sex, ensuring balanced allocation. Pharmacy staff masked the identity of treatments by over-encapsulating both placebo and naltrexone pills. During MRI scanning, participants were continuously monitored by a study physician, with real-time assessment of respiration, pulse oximetry, and vital signs to ensure safety throughout the infusion. 3D pseudo-Continuous Arterial Spin Labelling (3D-pCASL) data were acquired twice per visit: at baseline (pre-ketamine administration) and during the final 10 minutes of the ketamine infusion (**Figure 1B**).

### Participants

Participant details have been previously reported (9). Briefly, 26 adults (18-50 years) with MDD diagnosed according to DSM-5 completed both study arms. Inclusion required a Hamilton Depression Rating Scale (HAM-D) score of at least 18 and prior inadequate response to two or more antidepressants (minimum effective dose for ≥6 weeks) or one antidepressant and a course of evidence-based psychotherapy. Regular antidepressants (≥4 weeks) were permitted, except monoamine oxidase inhibitors (MAOIs). Exclusion criteria included pregnancy, breastfeeding, schizophrenia, schizoaffective or bipolar disorder, current substance dependence, high suicide risk, prior nonresponse or intolerance to ketamine, uncontrolled medical illnesses, and MRI contraindications. Complete ASL data sets were available for 25 participants, after data from one participant was excluded due to image artifact. See **eTable 1** for participant demographics of the included sample.

**Imaging Methods**

Detailed imaging methods are provided in the **Supplementary eMethods**. Briefly, all MRI data were acquired on a 3 Tesla General Electric (GE) Discovery MR750 scanner equipped with a 32-channel head coil. Regional CBF was measured at rest using 3D-pCASL with a post-labelling delay of 2025 ms and four control-label pairs collected to derive perfusion-weighted images. A proton density (PD) image was also acquired within the same series, after the control-label pairs, using identical readout parameters. The 3D Fast Spin Echo spiral multi-shot readout had eight interleaved spiral arms and 512 points per arm. Four background suppression pulses were employed. The PD image enabled computation of CBF maps in absolute, standard physiological units (mL blood/100 g tissue/min). High-resolution T1-weighted images were obtained for structural reference and spatial normalisation of the CBF maps.

*Image Processing*

3D-pCASL pre-processing used the ASAP (Automatic Software for ASL Processing) toolbox (37) which uses Statistical Parametric Mapping (SPM12) software. PD images were co-registered to each participant's T1-weighted image, and the resulting transformation was applied to the CBF maps. Each CBF map was then spatially normalised to MNI-152 template space, masked to exclude non-brain tissue, and spatially smoothed using a 6-mm Gaussian kernel.

*Analysis of 3D-pCASL Data*

**Global CBF:** Global CBF values were calculated by extracting mean signal from a grey matter mask using MarsBaR (38). White matter was excluded from the analysis due to the well-established insensitivity of ASL in that tissue. A linear mixed-effects (LME) model was used to assess the main effects of ketamine, pretreatment condition (naltrexone vs. placebo), and their interaction on global CBF, with participant ID included as a random effect. Analyses were implemented using R software (version 4.2.1) with the nlme package (39).

**Region of interest (ROI):** We selected nine pre-defined regions, based on prior literature, that have been implicated in ketamine's effects: sgACC area 25 (left and right), sgACC area 32, pgACC, dACC (left and right), thalamus, hippocampus, and anterior insula (see **Supplementary eMethods** and **eFigure 1**). Mean rCBF values for each ROI were extracted, and LME models were applied to examine the main effect of ketamine and ketamine-by-naltrexone interaction,

controlling for global grey matter CBF. Multiple comparisons were corrected using the

Benjamini-Hochberg method (FDR 5%) (40).

**Whole-Brain Voxel-Wise Analyses:** Whole-brain voxel-wise analyses were conducted in

SPM12 using a flexible factorial design. This approach allowed for the assessment of main and

interaction effects of ketamine and pretreatment condition on rCBF. Age and sex were

included as covariates to account for their influence on rCBF. Finally, global-grey matter CBF

was included as a covariate (i.e., global normalisation). Results without global normalisation

are presented as supplementary materials. Statistical maps were thresholded at $p < 0.05$,

voxel-wise (peak-level) FWE-corrected.

**Associations with Clinical and Subjective Measures:** We used partial Pearson correlations,

adjusting for global CBF, to examine relationships between baseline rCBF (pre-ketamine) and

day-1 changes in clinical scales (MADRS, QIDS-SR, Snaith-Hamilton Pleasure Scale (SHAPS),

Temporal Experience of Pleasure Scale - Anticipatory (TEPS-A), and Temporal Experience of

Pleasure Scale - Consummatory (TEPS-C)). During infusion, we computed relative CBF (rCBF／

global CBF) for each ROI and correlated these against day-1 clinical change scores, adjusting

for pre-infusion relative CBF. Analyses of acute subjective effects (CADSS; PSI subscales)

followed the same approach for baseline and infusion rCBF. All tests were run separately

under placebo and naltrexone, with Bonferroni correction across nine ROIs (α < 0.0056). To

compare placebo versus naltrexone correlations, we applied Steiger's Z-test (via r.test in the

psych package in R (41,42)).

**Receptor Density and CBF Correlation Analysis:** Spatial correlations between ketamine-

induced rCBF changes and receptor distributions, alongside the effect of naltrexone, were

examined using publicly available PET-derived receptor maps (MOR, KOR, NMDA, mGluR5,

$GABA_A$, and $GABA_A\alpha5$). To account for spatial autocorrelation, Spearman's correlations

between rCBF contrast maps and receptor density maps were corrected using BrainSMASH.

(43) (see **Supplementary eMethods** and **eFigure 2**). Given evidence for potential opioid,

dopaminergic and serotonergic interactions in ketamine's antidepressant effects (44–46), we

also analysed  dopaminergic ($D_1$ and $D_2$) and serotonergic PET maps ($5HT_{1A}$, $5HT_{1B}$, $5HT_{2A}$,

$5HT_4$, $5HT_6$, and 5HTT).

## Results

### Global CBF

Linear mixed-effects analysis revealed a significant main effect of ketamine on global grey-matter CBF ($F_{1,72}$ = 18.1, $p < 0.001$), with increased CBF during infusion in both the placebo-plus-ketamine (mean increase = 3.75 ± 5.01 ml/100 g/min) and naltrexone-plus-ketamine (mean increase = 3.25 ± 4.25 ml/100 g/min) conditions. A significant main effect of pretreatment condition was also observed ($F_{1,72}$ = 5.27, $p = 0.025$), with higher overall global CBF in the naltrexone condition (mean = 51.39 ± 8.31) compared to placebo (mean = 49.50 ± 8.88). No significant ketamine-by-pretreatment interaction was found ($F_{1,72}$ = 0.09, $p = 0.76$) (**Supplementary eFigure 3**).

### Region of interest analyses

Ketamine and pretreatment condition each had significant main effects on rCBF across all nine ROIs (FDR-adjusted $p < 0.05$), with increased rCBF during ketamine infusion and higher overall rCBF in the naltrexone condition. No significant interaction effects were observed (**Figure 2, Supplementary eTable 2**).

### Whole-brain analysis

Ketamine increased rCBF in a large frontal cluster encompassing the sgACC, pgACC and dACC, anterior PFC, bilateral insula, inferior frontal gyri and orbitofrontal cortex ($p < 0.05$ FWE-corrected) (**Figure 3, Supplementary eTable 3**). We did not observe any significant pretreatment condition or ketamine-by-pretreatment condition effects in the whole-brain voxel-wise analysis. For results without global normalisation see **Supplementary eFigure 3.**

### Regional CBF and clinical/subjective measure associations

In the placebo condition, significant positive partial correlations were observed between baseline rCBF in left and right sgACC-25 and day 1 depressive symptom improvement (MADRS and QIDS-SR). Lower baseline CBF predicted greater antidepressant response. These associations were absent under naltrexone (**Figure 4A–C).** Steiger's Z-tests demonstrated each association was significantly stronger under placebo than naltrexone: left sgACC-25–QIDS-SR

(t = 2.67, p = 0.014); right sgACC-25–MADRS (t = 2.18, p = 0.040); and right sgACC-25–QIDS-

SR (t = 2.55, p = 0.018).

In the placebo condition, changes in relative pgACC rCBF during ketamine infusion were

positively correlated with PSI delusional and perceptual distortion scores, whereas

hippocampal rCBF changes were negatively correlated with perceptual distortion. These

correlations were abolished under naltrexone (**Figure 4D–F**). Steiger's Z-tests demonstrated

each association was significantly stronger under placebo than naltrexone: pgACC–PSI

delusional (t = 6.12, p < 0.001), pgACC–PSI perceptual distortion (t = 8.46, p < 0.001), and

hippocampus–PSI perceptual distortion (t = –5.86, p < 0.001).

A positive correlation was also found between baseline left sgACC-25 rCBF and PSI anhedonia

under placebo (r = 0.625, p = 0.001), but not naltrexone (r = 0.322, p = 0.125). Conversely,

baseline thalamus rCBF was negatively correlated with PSI paranoia under naltrexone (r = –

0.562, p = 0.004), but not placebo (r = –0.322, p = 0.125). However, these correlations did not

differ significantly between conditions (t = 1.59, p = 0.13; t = 1.88, p = 0.073).

ΔCBF and receptor density profile associations

Spatial correlation analyses showed a significant association between ketamine-induced ΔCBF

and MOR distribution (r = 0.491 $p_{SA-corr}$ = 0.0289), and a weaker but significant correlation with

mGluR5 distribution (r = 0.290, $p_{SA-corr}$ = 0.0286) (**Figure 5 and Supplementary eTable 4**). For

the ketamine x naltrexone interaction contrast, significant correlations were observed with

MOR and GABA$_A$α5 receptor distributions (r = 0.530, $p_{SA-corr}$ = 0.0233 and r = 0.531, $p_{SA-corr}$ =

0.0013 respectively). No significant spatial correlations were found with KOR, NMDA, or

GABA$_A$ receptor maps.

See **Supplementary eFigure 4 and eTable 5** for dopaminergic and serotonergic receptor

density associations.

## Discussion

In this study, we used non-invasive perfusion MRI to examine the neurophysiological mechanisms underlying ketamine's rapid antidepressant effects and explored the impact of opioid receptor antagonism using naltrexone. Consistent with our hypothesis, ketamine significantly increased rCBF in the sgACC, pgACC and dACC as well as the thalamus. Additional rCBF increases were observed in the bilateral insula, hippocampus, and frontal regions, including the anterior PFC, inferior frontal gyri, and orbitofrontal cortex. Contrary to our hypothesis, naltrexone did not significantly attenuate these ketamine-induced CBF changes in any focal region. Instead, naltrexone was associated with increased global CBF. ROI analyses showed that ketamine-induced rCBF changes correlated with subjective effects and that baseline rCBF predicted next-day reductions in depression ratings. These relationships were abolished by naltrexone pretreatment. Finally, we found significant relationships between the spatial distribution of perfusion changes induced by ketamine and opioidergic, and glutamatergic systems (MOR and mGluR5), and between the spatial distribution of the naltrexone interaction effect on ketamine induced CBF changes and opioidergic and GABAergic systems (MOR and $GABA_A\alpha5$).

Our findings align with previous studies in healthy volunteers, where ketamine has been shown to increase CBF in similar regions, including anterior and subgenual areas of the cingulate, thalamus, and hippocampus (26,28,29,31,32). These regions are consistently implicated in the pathophysiology of major depression and in the therapeutic effects of antidepressant treatments (47–50). Specifically, hyperactivity in the sgACC is a well-established marker of depression, and successful treatment is often associated with normalisation of this region's activity (49,51–53). Our observation that lower baseline relative CBF in the sgACC-25 predicted greater antidepressant response to ketamine the next day (under the placebo condition) aligns with other studies showing relative hyperactivity in the sgACC (area 24, 25, 32) often predicts non-response to both drug and psychological treatments (54–56) and suggests that rCBF in this region could serve as a predictive biomarker for treatment outcomes.

We observed that under placebo pretreatment, ketamine-induced rCBF changes in the pgACC and hippocampus were associated with acute subjective effects, including perceptual

distortions and delusional thoughts. Notably, naltrexone pretreatment abolished these relationships, as well as the association between baseline sgACC-25 rCBF and delayed (24-hour) antidepressant effects. These findings suggest that the acute and delayed effects of ketamine may involve distinct neural circuits, both modulated by opioidergic systems. This differential mediation may help explain the inconsistent relationship between ketamine's immediate subjective effects and its longer-lasting antidepressant response (57).

Unexpectedly, naltrexone was associated with a global increase in CBF, but without significant focal effects. This finding could indicate a diffuse modulatory impact of naltrexone on neurovascular function, potentially through direct effects on cerebral vasculature or interference with endorphinergic mechanisms in CBF regulation (58–60). Prior studies using naloxone did not demonstrate similar effects (27), although methodological differences (e.g. partial brain coverage) or participant characteristics (healthy volunteers and patients with depression) may explain this discrepancy.

Our exploratory analysis revealed that the spatial distribution of ketamine-induced rCBF changes was significantly correlated with receptor density maps for MOR and mGluR5 receptors and the effect of naltrexone on the spatial distribution of ketamine induced CBF changes with MOR and GABAAα5 receptor maps. The absence of a correlation with NMDA receptor density (despite ketamine's established role as an NMDA receptor antagonist) may reflect limitations in the NMDA PET tracer used ([18F]GE-179), which has shown limited specificity (61). The association between ketamine's rCBF effects and mGluR5 is consistent with prior evidence showing that ketamine can reduce mGluR5 availability in humans, potentially reflecting downstream glutamatergic modulation (62,63). Notably, the significant association with GABAAα5 and the ketamine-by-naltrexone interaction highlights a potential modulatory role of GABAergic inhibition in opioid–glutamate crosstalk. GABA$_A$α5 subunit receptors, located in cortical and limbic brain regions associated with depression (64), facilitate inhibition via SST-expressing interneurons on dendrite-targeting projections (65,66). GABAergic interneurons have been identified as the cellular trigger for ketamine's rapid antidepressant actions, with evidence that GluN2B subunit deletion in SST interneurons blocks ketamine's behavioural efficacy in animal models (67). MORs are also located on GABAergic interneurons (68,69). It has been shown that MOR expression, specifically on SST interneurons is necessary for the acute and antidepressant-like responses to the atypical antidepressant

tianeptine (70). Through this circuit, activating MORs on SST interneurons can decrease their

activity, providing an additional mechanism that could contribute to the disinhibition of

glutamatergic pyramidal neurons.

Taken together, our findings support a speculative model whereby ketamine acts to inhibit SST

interneurons, both via NMDA antagonism and via direct or indirect effects on MORs, also

located on SST interneurons. This would lead to the disinhibition of pyramidal cells and an

acute glutamate burst (9). In the presence of naltrexone, direct MOR antagonist effects on the

SST interneurons would act to increase GABA release onto pyramidal cells dendrites, thereby

increasing the inhibitory balance and attenuating ketamine-induced increases in

glutamatergic activity (**Supplementary eFigure 5**). This is a selective model and the full range

of circuits and neurotransmitter systems at play is much more elaborate and multifaceted.

Indeed, our supplementary analysis also uncovered relationships between serotonergic

receptor density maps and the spatial distribution of ketamine CBF effects ($5\text{-HT1}_b$ and $5\text{-HT}_{2a}$)

and ketamine – naltrexone interaction effects with dopaminergic and serotonergic maps ($D_1$,

$D_2$, $5\text{-HT}_{1a}$, $5\text{-HT}_4$ and 5-HTT) (**Supplementary eFigure 4 and eTable 5**). This further supports

the view that opioid modulation is not an isolated effect but involves interactions with other

neurotransmitter systems, including glutamatergic, GABAergic, dopaminergic, and

serotonergic, all implicated in ketamine's antidepressant actions (1,45).

Strengths and Limitations

This study is the first to explore the impact of opioid receptor antagonism on acute CBF

changes induced by ketamine in patients with MDD using a randomised, double-blind,

crossover design. The use of 3D-pCASL imaging provided quantitative, non-invasive

measurements of CBF, enhancing the reliability of our findings. Our exploratory analysis

linking rCBF changes with receptor density profiles offers novel insights into the potential

neurotransmitter systems involved in ketamine's effects.

Several limitations should be acknowledged. Without a healthy control group, we are limited

to determine whether the observed findings are specific to individuals with MDD. The lack of

a placebo infusion arm also prevents us from conclusively attributing observed CBF changes

to ketamine rather than non-specific effects. While age and sex were included as covariates,

other factors like BMI and concurrent medications were not controlled in our within-subject

analyses. Additionally, receptor associations were based on PET maps from healthy

populations, which may not reflect distributions in MDD. Future studies using individualised

receptor mapping may provide greater precision.

## Conclusion

This study demonstrates that ketamine administration in MDD patients increases CBF in

regions critical for emotional processing, including the sgACC, pgACC, dACC, thalamus, insula,

and hippocampus. Regional baseline CBF predicted antidepressant response, while ketamine-

induced CBF changes were associated with acute subjective effects. However, these predictive

relationships were disrupted by naltrexone pretreatment. Our findings indicate that

ketamine's impact on brain perfusion is not solely mediated by glutamatergic mechanisms but

is also influenced by interactions with opioidergic and other neurotransmitter systems. The

spatial correlations between CBF changes and receptor density maps underscores this

complexity, suggesting that ketamine's effects may emerge from a dynamic interplay among

multiple neurotransmitter systems, including, but not limited to glutamatergic, opioidergic,

and GABAergic pathways.

Figures

357
**Figure 1: Study overview.** A) 26 participants with major depressive disorder (MDD) were enrolled in a within-
subject, randomised, crossover design. Each participant received oral placebo or naltrexone one hour before a
ketamine infusion (0.5 mg/kg over 40 minutes) during an MRI session at two separate visits. The two visits were
separated by a 2–4-week washout period. Participants were randomised into two groups: 13 participants
received placebo pretreatment at their first visit and naltrexone at their second; the remaining 13 participants
received naltrexone first, followed by placebo at the second visit. B) At each visit, participants completed pre-
dose clinical assessments prior to any drug administration. Oral placebo or naltrexone was administered one
hour before the ketamine infusion. During the MRI session, a high-resolution structural scan was followed by a
baseline (pre-infusion) 3D pseudo-Continuous Arterial Spin Labelling (pCASL) scan. Ketamine (0.5 mg/kg) was
then infused over 40 minutes while participants remained in the scanner. A second 3D-pCASL scan was acquired
during the final 10 minutes of the infusion. Immediately after the infusion, subjective measures were collected,
with participants asked to recall peak drug effects. Follow-up clinical assessments were conducted again 24 hours
post-infusion (Day 1).

**Figure 2: Regional CBF values and percentage change across regions of interest.** CBF values are shown for the Pre (pre-infusion) and Ketamine (during infusion) scans for each pretreatment condition (placebo and naltrexone). The thick lines represent the mean values for each condition. Panels represent the following ROIs: A) sgACC-25 (left), B) sgACC-25 (right), C) sgACC-32, D) pgACC, E) dACC (left), F) dACC (right), G) thalamus (bilateral), H) insula (bilateral), and I) hippocampus (bilateral). Boxplots to the right of each panel display the percentage change in CBF for placebo (P) and naltrexone (N) conditions. Box plot elements: Box spans the interquartile range (IQR) (25th–75th percentile), central line is the median (50th percentile), "+" marks the mean, whiskers extend to the lowest and highest values within 1.5 × IQR of the box, and values beyond that range are shown individually. Each plot shows data from participants with complete 3D-pCASL data sets (n = 25).

**Figure 3: The main effect of ketamine on CBF for the whole-brain voxel-wise analysis (with global normalisation).** Results overlaid on the SPM152 T1 template distributed with MRIcroGL The MNI z-axis is shown at the top of the figure. Statistical maps were thresholded at p < 0.05, voxel-wise (peak-level) FWE-corrected. The colour bar shows the t statistic.

**Figure 4: Baseline regional CBF predicts day 1 clinical measure changes and ketamine-induced regional CBF changes predict subjective measure scores for placebo pretreatment condition only.** A) Plot of relative sgACC-25 (right) CBF at baseline against day 1 MADRS change scores; B) Plot of relative sgACC-25 (right) CBF at baseline against day 1 QIDS-SR change scores; C) Plot of relative sgACC-25 (left) CBF at baseline against day 1 QIDS-SR change scores; D) Plot of relative pgACC CBF change during ketamine infusion and PSI delusional subscale scores; E) Plot of relative pgACC CBF change during ketamine infusion and PSI perceptual distortion subscale scores; F) Plot of relative Hippocampus CBF change during ketamine infusion and PSI perceptual distortion subscale scores.

**Figure 5. Associations between ΔCBF and receptor density profiles.** A) Main effect of ketamine under placebo (Ketamine > Pre-Ketamine) with Spearman correlations against each receptor map. B) Ketamine × Naltrexone interaction effect on CBF with Spearman correlations against each receptor map. Asterisks denote correlations significant after spatial-autocorrelation correction (* pSA-corr < 0.05) and after additional Benjamini–Hochberg FDR correction (** FDR-corr < 0.05).

## Acknowledgements

We thank all study participants, and the research nurses, radiographers, and support staff at the NIHR King's Clinical Research Facility for their invaluable assistance. This is independent research funded by a Medical Research Council Clinical Research Training Fellowship (grant number MR/T028084/1 awarded to L.A.J) and carried out at the NIHR (National Institute for Health and Care Research) Maudsley Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the Medical Research Council, the National Institute for Health and Care Research or the Department of Health and Social Care.

## Author Contributions

The study was conceptualised by L.A.J., J.M.S., A.H.Y. and M.A.M. Funding was obtained by L.A.J., J.M.S., A.H.Y. and M.A.M. Study methodology was developed by L.A.J., O.O, F.O.Z, J.M.S., A.H.Y. and M.A.M. L.A.J. led the investigation, project administration, data curation and formal analysis under the supervision of J.M.S., A.H.Y. and M.A.M. L.A.J. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The original draft was written by L.A.J., with review and editing by L.A.J., J.M.S., A.H.Y. and M.A.M. All authors have read, commented on and approved the final version of the manuscript.

## Competing Interests

**L.A.J:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **O.O:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **F.O.Z:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **J.M.S:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **A.H.Y:** Employed by Imperial College London; Honorary Consultant South London and Maudsley NHS Foundation Trust (NHS UK). Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: "An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression." Principal Investigator on "The Effects of Psilocybin on Cognitive Function in Healthy Participants". Principal Investigator on "The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)". Principal Investigator on ''A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy.'' (Janssen). Principal Investigator on '' An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD).'' (Janssen). Principal Investigator on ''A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.'' Principal Investigator on '' A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With

Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR.''
(Janssen). UK Chief Investigator for Compass; COMP006 & COMP007 studies. UK Chief Investigator for
Novartis MDD study MIJ821A12201. Grant funding (past and present): NIMH (USA); CIHR (Canada);
NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal
College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS
Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020. No
shareholdings in pharmaceutical companies. **M.A.M:** Has current funding from Nxera, Takeda and
Lundbeck and has acted as an advisor for Boehringer Ingelheim, Neurocentrx, Quolet Pharmaceuticals
and Nxera.

## References

1. Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021/02/12 ed. 2021 Feb 11;1–32.

2. Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020 Dec 1;277:831–41.

3. Zavaliangos-Petropulu A, Al-Sharif NB, Taraku B, Leaver AM, Sahib AK, Espinoza RT, et al. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2023 Apr 1;8(4):361–86.

4. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacol. 2017 May;42(6):1210–9.

5. Evans JW, Szczepanik J, Brutsche N, Park LT, Nugent AC, Zarate CA Jr. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biol Psychiatry [Internet]. 2018/03/28 ed. 2018 Feb 15; Available from: https://www.ncbi.nlm.nih.gov/pubmed/29580569

6. Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2021;26(7):3292–301.

7. Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacol. 2020 May;45(6):975–81.

8. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018/06/28 ed. 2018 Jul;70(3):621–60.

9. Jelen LA, Lythgoe DJ, Stone JM, Young AH, Mehta MA. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study. Nat Med. 2025 Jul 24;1–9.

10. Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solis O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry [Internet]. 2021/04/17 ed. 2021 Apr 15; Available from: https://www.ncbi.nlm.nih.gov/pubmed/33859356

11. Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A. 2020/01/17 ed. 2020 Feb 4;117(5):2656–62.

12. Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of
Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry.
2018/08/30 ed. 2018 Dec 1;175(12):1205–15.

13. Di Ianni T, Ewbank SN, Levinstein MR, Azadian MM, Budinich RC, Michaelides M, et al. Sex
dependence of opioid-mediated responses to subanesthetic ketamine in rats. Nat
Commun. 2024 Jan 30;15(1):893.

14. Levinstein MR, Carlton ML, Ianni TD, Ventriglia EN, Rizzo A, Gomez JL, et al. Mu opioid
receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse
liability. Biological Psychiatry [Internet]. 2022 Dec 24 [cited 2023 Jan 3];0(0). Available
from:            https://www.biologicalpsychiatryjournal.com/article/S0006-3223(22)01854-
6/fulltext

15. Jiang C, DiLeone RJ, Pittenger C, Duman RS. The endogenous opioid system in the medial
prefrontal cortex mediates ketamine's antidepressant-like actions. Transl Psychiatry. 2024
Feb 12;14(1):90.

16. Zhang F, Hillhouse TM, Anderson PM, Koppenhaver PO, Kegen TN, Manicka SG, et al.
Opioid receptor system contributes to the acute and sustained antidepressant-like effects,
but not the hyperactivity motor effects of ketamine in mice. Pharmacol Biochem Behav.
2021/07/06 ed. 2021 Jul 2;173228.

17. Pomrenze MB, Vaillancourt S, Llorach P, Rijsketic DR, Casey AB, Gregory N, et al. Ketamine
evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central
amygdala. Biological Psychiatry [Internet]. 2025 May 5 [cited 2025 Jun 4]; Available from:
https://www.sciencedirect.com/science/article/pii/S0006322325011771

18. Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation
of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol
Psychiatry. 2019/08/31 ed. 2019 Dec;24(12):1779–86.

19. Yoon G, Petrakis IL, Krystal JH. Association of Combined Naltrexone and Ketamine With
Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use
Disorder. JAMA Psychiatry. 2019 Mar 1;76(3):337.

20. Zhang K, Hashimoto K. Lack of Opioid System in the Antidepressant Actions of Ketamine.
Biol Psychiatry. 2018/12/14 ed. 2019 Mar 15;85(6):e25–7.

21. Marton T, Barnes DE, Wallace A, Woolley J. Concurrent Use of Buprenorphine,
Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity. Biological
Psychiatry. 2019;85(15):e75–6.

22. Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA. Glial and
neuronal control of brain blood flow. Nature. 2010 Nov;468(7321):232–43.

23. Mervin LH, Mitricheva E, Logothetis NK, Bifone A, Bender A, Noori HR. Neurochemical
underpinning of hemodynamic response to neuropsychiatric drugs: A meta- and cluster
analysis of preclinical studies. J Cereb Blood Flow Metab. 2021 Apr 1;41(4):874–85.

24. Simon AB, Buxton RB. Understanding the dynamic relationship between cerebral blood
flow and the BOLD signal: Implications for quantitative functional MRI. Neuroimage. 2015
Aug 1;116:158–67.

25. Petcharunpaisan S, Ramalho J, Castillo M. Arterial spin labeling in neuroimaging. World J
Radiol. 2010/12/17 ed. 2010 Oct 28;2(10):384–98.

26. Pollak TA, De Simoni S, Barimani B, Zelaya FO, Stone JM, Mehta MA. Phenomenologically
distinct psychotomimetic effects of ketamine are associated with cerebral blood flow
changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.
Psychopharmacology (Berl). 2015/10/07 ed. 2015 Dec;232(24):4515–24.

27. Zelaya FO, Zois E, Muller-Pollard C, Lythgoe DJ, Lee S, Andrews C, et al. The response to
rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling.
MAGMA. 2011/11/25 ed. 2012 Apr;25(2):163–75.

28. Bojesen KB, Andersen KA, Rasmussen SN, Baandrup L, Madsen LM, Glenthoj BY, et al.
Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are
Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy
Volunteers. Front Psychiatry. 2018/02/23 ed. 2018;9:22.

29. Bryant JE, Frölich M, Tran S, Reid MA, Lahti AC, Kraguljac NV. Ketamine induced changes
in regional cerebral blood flow, interregional connectivity patterns, and glutamate
metabolism. Journal of Psychiatric Research. 2019 Oct 1;117:108–15.

30. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. Effects of Noncompetitive
NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with
Schizophrenia. Neuropsychopharmacol. 2005 Dec;30(12):2275–82.

31. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential Regional Cerebral
Blood Flow Brain Scans Using PET with H215O Demonstrate Ketamine Actions in CNS
Dynamically. Neuropsychopharmacol. 2001 Aug;25(2):165–72.

32. Långsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. Effects of Subanesthetic
Doses of Ketamine on Regional Cerebral Blood Flow, Oxygen Consumption, and Blood
Volume in Humans. Anesthesiology. 2003 Sep 1;99(3):614–23.

33. Rowland LM, Beason-Held L, Tamminga CA, Holcomb HH. The interactive effects of
ketamine and nicotine on human cerebral blood flow. Psychopharmacology. 2010 Mar
1;208(4):575–84.

34. Gärtner M, Weigand A, Meiering MS, Weigner D, Carstens L, Keicher C, et al. Region- and
time- specific effects of ketamine on cerebral blood flow: a randomized controlled trial.
Neuropsychopharmacol. 2023 May 25;1–7.

35. Gonzalez S, Vasavada MM, Njau S, Sahib AK, Espinoza R, Narr KL, et al. Acute changes in
cerebral blood flow after single-infusion ketamine in major depression: A pilot study.
Neurology, Psychiatry and Brain Research. 2020 Dec 1;38:5–11.

36. Sahib AK, Loureiro JR, Vasavada M, Kubicki A, Joshi S, Wang K, et al. Single and repeated
ketamine treatment induces perfusion changes in sensory and limbic networks in major
depressive disorder. Eur Neuropsychopharmacol. 2020 Apr;33:89–100.

37. Mato Abad V, García-Polo P, O'Daly O, Hernández-Tamames JA, Zelaya F. ASAP (Automatic
Software for ASL Processing): A toolbox for processing Arterial Spin Labeling images.
Magnetic Resonance Imaging. 2016 Apr 1;34(3):334–44.

38. Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM
toolbox. In Sendai, Japan; 2002.

39. Pinheiro J, Bates D. nlme: Linear and Nonlinear Mixed Effects Models [Internet]. 2022.
Available from: https://cran.r-project.org/web/packages/nlme/nlme.pdf

40. Feser WJ, Fingerlin TE, Strand MJ, Glueck DH. CALCULATING AVERAGE POWER FOR THE
BENJAMINI-HOCHBERG PROCEDURE. J Stat Theory Appl. 2009;8(3):325–52.

41. Revelle W. psych: Procedures for Psychological, Psychometric, and Personality Research
[Internet].        2022.        Available        from:        https://cran.r-
project.org/web/packages/psych/index.html

42. Steiger JH. Testing Pattern Hypotheses On Correlation Matrices: Alternative Statistics And
Some Empirical Results. Multivariate Behavioral Research. 1980 Jul 1;15(3):335–52.

43. Burt JB, Helmer M, Shinn M, Anticevic A, Murray JD. Generative modeling of brain maps
with spatial autocorrelation. NeuroImage. 2020 Oct 15;220:117038.

44. Jelen LA, Stone JM, Young AH, Mehta MA. The opioid system in depression. Neurosci
Biobehav Rev. 2022 Sep;140:104800.

45. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. J Psychopharmacol.
2020/11/07 ed. 2021 Feb;35(2):109–23.

46. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function:
meta-analysis and review of the implications for neuropsychiatric disorders. Mol
Psychiatry. 2017/10/04 ed. 2018 Jan;23(1):59–69.

47. Drevets W, Videen T, Price J, Preskorn S, Carmichael S, Raichle M. A functional anatomical
study of unipolar depression. J Neurosci. 1992 Sep 1;12(9):3628–41.

48. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood
disorders. CNS Spectr. 2008/08/16 ed. 2008 Aug;13(8):663–81.

49. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain
stimulation for treatment-resistant depression. Neuron. 2005/03/08 ed. 2005 Mar
3;45(5):651–60.

50. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal
Limbic-Cortical Function and Negative Mood: Converging PET Findings in Depression and
Normal Sadness. AJP. 1999 May 1;156(5):675–82.

51. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Differences in
brain glucose metabolism between responders to CBT and venlafaxine in a 16-week
randomized controlled trial. Am J Psychiatry. 2007 May;164(5):778–88.

52. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin
Invest. 2009 Apr;119(4):717–25.

53. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional
metabolic effects of fluoxetine in major depression: serial changes and relationship to
clinical response. Biological Psychiatry. 2000 Oct 15;48(8):830–43.

54. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain
metabolic changes in patients with major depression treated with either paroxetine or
interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001 Jul;58(7):631–40.

55. Konarski JZ, Kennedy SH, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Predictors of
nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in
major depressive disorder. J Psychiatry Neurosci. 2009 May;34(3):175–80.

56. McGrath CL, Kelley ME, Dunlop BW, Holtzheimer PE, Craighead WE, Mayberg HS.
Pretreatment brain states identify likely nonresponse to standard treatments for
depression. Biol Psychiatry. 2014 Oct 1;76(7):527–35.

57. Ballard ED, Zarate CA. The role of dissociation in ketamine's antidepressant effects. Nat
Commun. 2020 Dec 22;11(1):6431.

58. Benyó Z, Wahl M. Opiate receptor-mediated mechanisms in the regulation of cerebral
blood flow. Cerebrovasc Brain Metab Rev. 1996;8(4):326–57.

59. Sa´ndor P, De Jong W, De Wied D. Endorphinergic mechanisms in cerebral blood flow
autoregulation. Brain Research. 1986 Oct 29;386(1):122–9.

60. Turner DM, Kassell NF, Sasaki T, Comair YG, Boarini DJ, Beck DO. Effects of naloxone on
cerebral blood flow and metabolism in isoflurane/nitrous oxide-anesthetized dogs.
Neurosurgery. 1984 Jun;14(6):688–96.

61. Schoenberger M, Schroeder FA, Placzek MS, Carter RL, Rosen BR, Hooker JM, et al. In vivo
[18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges
in rodents and non-human primates. ACS Chem Neurosci. 2018 Feb 21;9(2):298–305.

62. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo
ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor
subtype 5. Biol Psychiatry. 2015 Feb 1;77(3):266–75.

63. Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-
induced reduction in mGluR5 availability is associated with an antidepressant response:
an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018 Apr
1;23(4):824–32.

64. Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and
Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019
Apr;102(1):75–90.

65. Fee C, Banasr M, Sibille E. Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron
Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. Biological
Psychiatry. 2017 Oct;82(8):549–59.

66. Schulz JM, Knoflach F, Hernandez MC, Bischofberger J. Dendrite-targeting interneurons
control synaptic NMDA-receptor activation via nonlinear α5-GABAA receptors. Nature
Communications. 2018;9(1).

67. Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, et al. GABA interneurons are the
cellular trigger for ketamine's rapid antidepressant actions. J Clin Invest. 2019/11/20 ed.
2020 Mar 2;130(3):1336–49.

68. Jiang C, Wang X, Le Q, Liu P, Liu C, Wang Z, et al. Morphine coordinates SST and PV
interneurons in the prelimbic cortex to disinhibit pyramidal neurons and enhance reward.
Mol Psychiatry. 2021 Apr;26(4):1178–93.

69. Taki K, Kaneko T, Mizuno N. A group of cortical interneurons expressing mu-opioid
receptor-like immunoreactivity: a double immunofluorescence study in the rat cerebral
cortex. Neuroscience. 2000;98(2):221–31.

70. Han J, Andreu V, Langreck C, Pekarskaya EA, Grinnell SG, Allain F, et al. Mu opioid receptors
on hippocampal GABAergic interneurons are critical for the antidepressant effects of
tianeptine. Neuropsychopharmacology. 2022 Jun;47(7):1387–97.